For research use only. Not for therapeutic Use.
Glymidine sodium is an oral active antidiabetic. Glymidine sodium is the inhibitor of hepatic lipolysis. Glymidine sodium inhibits the glucose formation and supresses the elevated pyruvate oxidation which results from the inhibition of endogenous lipid mobilization[1].
| Catalog Number | I028154 |
| CAS Number | 3459-20-9 |
| Synonyms | sodium;benzenesulfonyl-[5-(2-methoxyethoxy)pyrimidin-2-yl]azanide |
| Molecular Formula | C13H14N3NaO4S |
| Purity | ≥95% |
| InChI | InChI=1S/C13H14N3O4S.Na/c1-19-7-8-20-11-9-14-13(15-10-11)16-21(17,18)12-5-3-2-4-6-12;/h2-6,9-10H,7-8H2,1H3;/q-1;+1 |
| InChIKey | NUQDEHHKOXSIEA-UHFFFAOYSA-N |
| SMILES | COCCOC1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=CC=C2.[Na+] |
| Reference | [1]. Menahan LA, et al. The role of endogenous lipid in gluconeogenesis and ketogenesis of perfused rat liver. Eur J Biochem. 1969;9(2):182-188. |
